:max_bytes(150000):strip_icc()/BloodPressureMedicationRecall-10.30-d1cd2aee074349f8ba256b8a4eb36bc4.png "BloodPressureMedicationRecall-10.30-d1cd2aee074349f8ba256b8a4eb36bc4.png")
FDA Recalls Over 580,000 Bottles of Blood Pressure Medication Due to Cancer-Causing Chemical
The Food and Drug Administration (FDA) announced today a nationwide recall of more than 580,000 bottles of blood pressure medication due to the presence of imidazole, a chemical identified as a potential carcinogen.
The recall impacts multiple lots of losartan potassium tablets, a commonly prescribed medication for hypertension. Specifically, the affected products are manufactured by Teva Pharmaceutical Industries and include various strengths and sizes. The FDA stated the impurity, imidazole, was found above acceptable safety limits. Patients taking these medications are advised not to stop taking their medication without consulting a doctor, as abruptly stopping blood pressure medication can be dangerous.
According to the FDA website, the agency became aware of the issue through routine testing. “The FDA’s priority is patient safety, and we are taking action to remove these products from the market,” an FDA spokesperson said in a statement. The recall includes bottles distributed across the United States. Individuals who are concerned about whether their medication is affected can find detailed information, including specific lot numbers, on the FDA’s recall page.
The presence of potentially carcinogenic impurities in medications is a growing concern for regulatory agencies and highlights the complexities of pharmaceutical manufacturing. The FDA is continuing to investigate the source of the contamination and will provide updates as they become available.
